Cargando…

Suboptimal Baseline Serum Vitamin B12 Is Associated With Cognitive Decline in People With Alzheimer’s Disease Undergoing Cholinesterase Inhibitor Treatment

OBJECTIVES: Cholinesterase inhibitors (ChEIs) are the mainstream treatment for delaying cognitive decline in Alzheimer’s disease (AD). Low vitamin B12 is associated with cognitive dysfunction, and its supplementation has been applied as the treatment for certain types of reversible dementia. The pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Hsiao Shan, Huang, Li Kai, Lee, Yao Tung, Chan, Lung, Hong, Chien Tai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954104/ https://www.ncbi.nlm.nih.gov/pubmed/29867734 http://dx.doi.org/10.3389/fneur.2018.00325

Ejemplares similares

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis
por: Kennedy, Richard E., et al.
Publicado: (2018)

Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
por: Xu, Hong, et al.
Publicado: (2021)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Vitamin B12 and cognitive decline
por: Tasdemir, Serdar, et al.
Publicado: (2015)

China suboptimal health cohort study: rationale, design and baseline characteristics
por: Wang, Youxin, et al.
Publicado: (2016)

Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors
por: Teipel, Stefan J., et al.
Publicado: (2018)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

The Role of Suboptimal Home-Measured Blood Pressure Control for Cognitive Decline
por: Yaneva-Sirakova, Teodora, et al.
Publicado: (2012)

The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
por: Pourtaher, Hormoz, et al.
Publicado: (2023)

Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection?
por: Allam, Appa Rao, et al.
Publicado: (2006)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Baseline lymphocyte and cholinesterase levels may be the predictors of chronic herbal drug–induced liver injury
por: Zeng, Zhan, et al.
Publicado: (2022)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
por: Ortner, Marion, et al.
Publicado: (2020)

Potential of Vitamin B6 Dioxime Analogues to Act as Cholinesterase Ligands
por: Gašo Sokač, Dajana, et al.
Publicado: (2022)

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
por: Abdullah, Laila, et al.
Publicado: (2020)

Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease
por: Wang, Qing, et al.
Publicado: (2022)

Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis
por: Chen, Jia-Hung, et al.
Publicado: (2021)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Cholinesterase Research
por: Korabecny, Jan, et al.
Publicado: (2021)

Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia
por: Zuin, Marco, et al.
Publicado: (2022)

Cognitive and Affective Changes in Mild to Moderate Alzheimer’s Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A 6-Month Observational Study
por: Spalletta, Gianfranco, et al.
Publicado: (2014)

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
por: Dou, Kai-Xin, et al.
Publicado: (2018)

Vitamin B3-Based Biologically Active Compounds as Inhibitors of Human Cholinesterases
por: Zandona, Antonio, et al.
Publicado: (2020)

Evaluating the protective effects of vitamin C on serum and erythrocyte cholinesterase activity of male rats exposed to malathion
por: Taherdehi, Faezeh Ghorbani, et al.
Publicado: (2016)

A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease
por: Khan, Mohd. Babu, et al.
Publicado: (2018)

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
por: Amat-ur-Rasool, Hafsa, et al.
Publicado: (2021)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment
por: Gupta, Shraddha Manish, et al.
Publicado: (2023)

Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study
por: Colombo, Delia, et al.
Publicado: (2018)

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
por: Campbell, Noll, et al.
Publicado: (2008)

Synthesis of Brominated 2-Phenitidine Derivatives as Valuable Inhibitors of Cholinesterases for the Treatment of Alzheimer’s Disease
por: Abbasi, Muhammad Athar, et al.
Publicado: (2014)

Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story
por: Lam, Benjamin, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_23sicp77nqt5v54sd92k66ckpk